Anemia of Inflammation during Human Pregnancy Does Not Affect Newborn Iron Endowment. Issue 3 (12th March 2018)

• Record Type: Journal Article
• Authors: Abioye, Ajibola I; Park, Sangshin; Ripp, Kelsey; McDonald, Emily A; Kurtis, Jonathan D; Wu, Hannah; Pond-Tor, Sunthorn; Sharma, Surendra; Ernerudh, Jan; Baltazar, Palmera; Acosta, Luz P; Olveda, Remigio M; Tallo, Veronica; Friedman, Jennifer F
• Is Part Of: Journal of nutrition. Volume 148:Issue 3(2018)
• Page Start: 427
• Page End: 436
• Publication Date: 2018-03-12
• Subjects: iron-deficiency anemia -- non–iron deficiency anemia -- anemia of inflammation -- pregnancy -- Schistosoma japonicum -- biomarker -- hepcidin -- sTfR; Nutrition -- Periodicals; Diet -- Periodicals; 613.205
• DOI: 10.1093/jn/nxx052
• Languages: English
• ISSNs: 0022-3166

Abstract

Abstract: Background: To our knowledge, no studies have addressed whether maternal anemia of inflammation (AI) affects newborn iron status, and few have addressed risk factors for specific etiologies of maternal anemia. Objectives: The study aims were to evaluate 1 ) the contribution of AI and iron deficiency anemia (IDA) to newborn iron endowment, 2 ) hepcidin as a biomarker to distinguish AI from IDA among pregnant women, and 3 ) risk factors for specific etiologies of maternal anemia. Methods: We measured hematologic biomarkers in maternal blood at 12 and 32 wk of gestation and in cord blood from a randomized trial of praziquantel in 358 pregnant women with Schistosoma japonicum in The Philippines. IDA was defined as anemia with serum ferritin <30 ng/mL and non-IDA (NIDA), largely due to AI, as anemia with ferritin ≥30 ng/mL. We identified cutoffs for biomarkers to distinguish IDA from NIDA by using area under the curve (AUC) analyses and examined the impact of different causes of anemia on newborn iron status (primary outcome) by using multivariate regression modeling. Results: Of the 358 mothers, 38% ( n = 136) had IDA and 9% ( n = 32) had NIDA at 32 wk of gestation. At 32 wk of gestation, serum hepcidin performed better than soluble transferrin receptor (sTfR) in identifying women with NIDA compared with the rest of the cohort (AUCs: 0.75 and 0.70, respectively) and in identifying women with NIDA among women with anemia (0.73 and 0.72, respectively). The cutoff that optimally distinguished women with NIDA from women with IDA in our cohort was 6.1 µg/L. Maternal IDA, but not NIDA, was associated with significantly lower newborn ferritin (114.4 ng/mL compared with 148.4 µg/L; P = 0.042). Conclusions: Hepcidin performed better than sTfR in identifying pregnant women with NIDA, but its cost may limit its use. Maternal IDA, but not NIDA, is associated with decreased newborn iron stores, emphasizing the need to identify this cause and provide iron therapy. This trial was registered at www.clinicaltrials.gov as NCT00486863.